Advanced search
Publication Cover
Acta Cardiologica Volume 77, 2022 - Issue 2
Submit an article Journal homepage
158
Views
0
CrossRef citations to date
0
Altmetric
Original Scientific Papers

Clinical outcomes of patients who received a lower dose of non-vitamin K antagonist oral anticoagulants for the medical management of acute pulmonary embolism

Ji Yeon ShinDepartment of Cardiology and Medical Research Institute, Pusan National University Hospital, Busan, South KoreaView further author information
,
Jeong Cheon ChoeDepartment of Cardiology and Medical Research Institute, Pusan National University Hospital, Busan, South KoreaView further author information
,
Jin Hee AhnDepartment of Cardiology and Medical Research Institute, Pusan National University Hospital, Busan, South KoreaView further author information
,
Hye Won LeeDepartment of Cardiology and Medical Research Institute, Pusan National University Hospital, Busan, South KoreaView further author information
,
Jun-Hyok OhDepartment of Cardiology and Medical Research Institute, Pusan National University Hospital, Busan, South KoreaView further author information
,
Jung Hyun ChoiDepartment of Cardiology and Medical Research Institute, Pusan National University Hospital, Busan, South KoreaView further author information
,
Han Cheol LeeDepartment of Cardiology and Medical Research Institute, Pusan National University Hospital, Busan, South KoreaView further author information
,
Kwang Soo ChaDepartment of Cardiology and Medical Research Institute, Pusan National University Hospital, Busan, South KoreaView further author information
,
Taek Jong HongDepartment of Cardiology and Medical Research Institute, Pusan National University Hospital, Busan, South KoreaView further author information
&
Jin Sup ParkDepartment of Cardiology and Medical Research Institute, Pusan National University Hospital, Busan, South KoreaCorrespondence[email protected]
View further author information
 show all
Pages 122-129 | Received 10 Nov 2020, Accepted 15 Jan 2021, Published online: 08 Mar 2021

References

  • Tagalakis V, Patenaude V, Kahn SR, et al. Incidence of and mortality from venous thromboembolism in a real-world population: the Q-VTE Study Cohort. Am J Med. 2013;126:832 e13–21.
  • Bikdeli B, Wang Y, Jimenez D, et al. Pulmonary embolism hospitalization, readmission, and mortality rates in US older adults, 1999–2015. JAMA. 2019;322(6):574–576.
  • Hong J, Lee JH, Yhim H-Y, et al. Incidence of venous thromboembolism in Korea from 2009 to 2013. PLoS One. 2018;13(1):e0191897.
  • Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST Guideline and Expert Panel Report. Chest. 2016;149(2):315–352.
  • Iorio A, Kearon C, Filippucci E, et al. Risk of recurrence after a first episode of symptomatic venous thromboembolism provoked by a transient risk factor: a systematic review. Arch Intern Med. 2010;170(19):1710–1716.
  • Castellucci LA, Cameron C, Le Gal G, et al. Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis. BMJ. 2013;347(aug30 1):f5133–f5133.
  • Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369(9):799–808.
  • Bauersachs R. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363:2499–2510.
  • Buller HR. Edoxaban versus Warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013;369:1406–1415.
  • Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus Warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361(24):2342–2352.
  • Vasanthamohan L, Boonyawat K, Chai-Adisaksopha C, et al. Reduced-dose direct oral anticoagulants in the extended treatment of venous thromboembolism: a systematic review and meta-analysis. J Thromb Haemost. 2018;16(7):1288–1295.
  • Staerk L, Gerds TA, Lip GYH, et al. Standard and reduced doses of dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation: a nationwide cohort study. J Intern Med. 2018;283(1):45–55.
  • Xue Z, Zhang H. Non-vitamin K antagonist oral anticoagulants versus warfarin in Asians with atrial fibrillation: meta-analysis of randomized trials and real-world studies. Stroke. 2019;50(10):2819–2828.
  • Yao X, Shah ND, Sangaralingham LR, et al. Non-vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction. J Am Coll Cardiol. 2017;69(23):2779–2790.
  • Kim Y-H, Shim J, Tsai C-T, et al.; XANAP investigators. XANAP: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation in Asia. J Arrhythm. 2018;34(4):418–427.
  • Trujillo-Santos J, Di Micco P, Dentali F, et al. RIETE Investigators. Real-life treatment of venous thromboembolism with direct oral anticoagulants: the influence of recommended dosing and regimens. Thromb Haemost. 2017;117(2):382–389.
  • Chopard R, Serzian G, Humbert S, et al. Non-recommended dosing of direct oral anticoagulants in the treatment of acute pulmonary embolism is related to an increased rate of adverse events. J Thromb Thrombolysis. 2018;46(3):283–291.
  • January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. Circulation. 2019;140(2):e125–e151.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Novo Nordisk – Driving change to defeat serious chronic diseases.
Bristol Myers Squibb – symposium on hypertrophic cardiomyopathy.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.